Benzbromarone
Based on 10 publication(s) in Google Scholar
Benzbromarone is an orally active anti-gout agent. Benzbromarone has anti-infammatory, anti-oxidative stress and nephroprotective effects. Benzbromarone can be used for the research of hyperuricemia and gout.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 3562-84-3
- Formula: C17H12Br2O3
- Molecular Weight:424.08
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Benzbromarone
More- Nat Commun. 2025 Jul 16;16(1):6551. [Abstract]
- Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
- Adv Sci (Weinh). 2024 Nov 29:e2409126. [Abstract]
- Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]
- Stem Cell Res Ther. 2020 May 26;11(1):200. [Abstract]
- Anal Chem. 2025 Jun 3;97(21):11099-11109. [Abstract]
- Phytother Res. 2024 Dec;38(12):5918-5929. [Abstract]
- Int Immunopharmacol. 2024 Oct 10;143(Pt 1):113308. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- bioRxiv. 2026 Apr 30.
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
WB
All Caspase Isoforms
More
Biological Activity
|
IL-1β |
IL-8 |
Caspase-8 |
Caspase 9 |
Caspase 3 |
Bcl-2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
0.3 μM
Compound: benzbromarone
|
Inhibition of human URAT1-mediated urate uptake in HEK293 cells
Inhibition of human URAT1-mediated urate uptake in HEK293 cells
|
[PMID: 17325024] |
| HEK-293T | IC50 |
0.12 μM
Compound: 2
|
Inhibition of human URAT1 expressed in HEK293T cells assessed as reduction in [14C]uric acid uptake measured after 5 mins by liquid scintillation counting method
Inhibition of human URAT1 expressed in HEK293T cells assessed as reduction in [14C]uric acid uptake measured after 5 mins by liquid scintillation counting method
|
[PMID: 28351592] |
| MDCK | IC50 |
35 nM
Compound: 7, benzbromarone
|
Inhibition of human URAT1 expressed in human MDCK cells
Inhibition of human URAT1 expressed in human MDCK cells
|
[PMID: 21449597] |
| MDCK | EC50 |
39 μM
Compound: 3
|
Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay
Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay
|
[PMID: 25856229] |
| MDCK | EC50 |
39 μM
Compound: 21
|
Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 2 days by plaque reduction assay
Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 2 days by plaque reduction assay
|
[PMID: 27046062] |
| RPTEC | IC50 |
6.8 μM
Compound: BBR
|
Inhibition of uric acid uptake in human RPTEC
Inhibition of uric acid uptake in human RPTEC
|
[PMID: 33684442] |
| S2 | IC50 |
4.6 μM
Compound: Benzbromarone
|
TP_TRANSPORTER: inhibition of Urate uptake (Urate: 300 uM) in OAT1-expressing S2 cells
TP_TRANSPORTER: inhibition of Urate uptake (Urate: 300 uM) in OAT1-expressing S2 cells
|
[PMID: 12472777] |
| Sf9 | IC50 |
4 μM
Compound: Benzbromarone
|
Inhibition of human MRP1 expressed in Spodoptera frugiperda Sf9 cells assessed as inhibition of NEM-GS-induced vanadate-sensitive ATPase activity measured by generation of inorganic phosphate by spectrophotometry in presence of glutathione
Inhibition of human MRP1 expressed in Spodoptera frugiperda Sf9 cells assessed as inhibition of NEM-GS-induced vanadate-sensitive ATPase activity measured by generation of inorganic phosphate by spectrophotometry in presence of glutathione
|
[PMID: 21530277] |
| Sf9 | IC50 |
4 μM
Compound: Benzbromarone
|
Inhibition of Homo sapiens (human) MRP1 expressed in Sf9 cell membranes assessed as decrease in N-ethyl-maleimide-glutathione-induced inorganic phosphate production by spectrophotometric analysis in presence of glutathione
Inhibition of Homo sapiens (human) MRP1 expressed in Sf9 cell membranes assessed as decrease in N-ethyl-maleimide-glutathione-induced inorganic phosphate production by spectrophotometric analysis in presence of glutathione
|
10.1007/s00044-012-9994-0 |
| Vero | IC50 |
31.83 μg/mL
Compound: Benzbromarone
|
Cytotoxicity against african green monkey Vero cells measured after 48 hrs by MTT assay
Cytotoxicity against african green monkey Vero cells measured after 48 hrs by MTT assay
|
[PMID: 38547733] |
Benzbromarone (5-20 μM, 24 h) protects against propofol (HY-B0649)‑induced cytotoxicity in Human brain microvascular endothelial cells (HBMVECs)[1].
Benzbromarone (5-20 μM, 24 h) mitigates propofol (HY-B0649)‑induced oxidative stress and inhibits expression of pro‑inflammatory cytokines and Chemokines in HBMVECs[1].
Benzbromarone (1-100 μM, 2-24 h) activats the NRF2 signaling pathway in HepG2 cells[2].
Benzbromarone (1-30 μM, 24 h) promotes degradation of HSP47 to ameliorate collagen overproduction in human keloid fibroblasts[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HBMVECs
-
Concentration:5 μM, 10 μM, 20 μM
-
Incubation Time:24 h
-
Result:Improved the viability reduced by propofol.
-
Cell Line:HepG2 cells
-
Concentration:1 μM, 2 μM, 5 μM, 10 μM, 20 μM, 50 μM, 100 μM
-
Incubation Time:2 h, 6 h, 24 h
-
Result:Increased NRF2 protein expression in HepG2 cells exposed for 2 h, 6 h and 24 h at any concentration. Significantly accumulated the protein of NRF2 in the nuclear fraction after exposure to 100 μM at any time point. Caused an increase in the protein expression of TRX1 and TRX2. Significantly increased the ratio of oxidized TRX2 to reduced TRX2 at a concentration of 100 μM.
Benzbromarone (10 mg/kg, Oral gavage, once a day for 14 consecutive days) attenuates the nephrotoxicity caused by cisplatin(HY-17394) in cisplatin treated rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:High fat diet (HFD)-induced obese (DIO) mice[3]
-
Dosage:25 mg/kg, 50 mg/kg
-
Administration:Intragastric (i.g.)
-
Result:Aggravated lipid accumulation in the liver of DIO mice. Significantly increased triglyceride accumulation and AST, ALT levels. Regulated multiple lipid metabolism genes and the expression of protein markers associated with apoptosis, endoplasmic reticulum stress, and inflammation in the liver of DIO mice.
-
Animal Model:Cisplatin treated rats[2]
-
Dosage:10 mg/kg
-
Administration:Oral gavage (p.o.)
-
Result:Ameliorated the elevation in serum creatinine and blood urea nitrogen (BUN) levels induced by cisplatin. Counteracted oxidative stress induced by cisplatin and enhances anti-oxidant defenses in kidney. Alleviated the inflammatory events of nephrotoxicity induced by cisplatin. Attenuated cisplatin-induced apoptosis.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 3562-84-3
-
Appearance Solid
-
Molecular Weight 424.08
-
Formula C17H12Br2O3
-
Color White to off-white
-
SMILES
O=C(C1=CC(Br)=C(O)C(Br)=C1)C2=C(CC)OC3=CC=CC=C23
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 Jul 16;16(1):6551. PMID: 40670375 -
Acta Pharm Sin B
2025 Dec;15(12):6382-6398. PMID: 41477334
Benzbromarone purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2025 Dec;15(12):6382-6398. [Abstract]
Inhibition of 14C-urate transport by Benzbromarone in URAT1EM and its mutants.
-
Adv Sci (Weinh)
Slow Metabolism-Driven Amplification of Hepatic PPARγ Agonism Mediates Benzbromarone-Induced Obesity-Specific Liver Injury. [Abstract]2024 Nov 29:e2409126. PMID: 39611414 -
Adv Sci (Weinh)
ANO1-Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer-Associated Fibroblasts. [Abstract]2023 Aug;10(24):e2300881. PMID: 37341301
Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]
Benzbromarone (BBR) (1-100 μM; 72 h) inhibited in vitro proliferation of multiple human GC and CRC cell lines.
Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]
Benzbromarone (BBR) (50 mg/kg; p.o.; once every other day for 3 weeks) showed anti-tumor effectiveness in ANO1-positive GC PDX mice.
Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]
Benzbromarone (BBR) (50 mg/kg; p.o.; once every other day for 3 weeks) evidently augmented the anti-tumor effect of anti-PD-1 antibody against MC38/CT26 xenograft mice.
Benzbromarone purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 Aug;10(24):e2300881. [Abstract]
Benzbromarone (BBR) (1-100 μM) dose-dependently inhibited ANO1's protein expression in multiple GI cancer cells.
-
Stem Cell Res Ther
Co-transplantation with adipose-derived cells to improve parathyroid transplantation in a mice model. [Abstract]2020 May 26;11(1):200. PMID: 32456711 -
Anal Chem
Exposome-Scale Investigation of Cl-/Br-Containing Chemicals Using High-Resolution Mass Spectrometry, Multistage Machine Learning, and Cloud Computing. [Abstract]2025 Jun 3;97(21):11099-11109. PMID: 40401576 -
Phytother Res
α-Mangostin Attenuates Blood Pressure and Reverses Vascular Remodeling by Balancing ACE/AT1R and ACE2/Ang-(1-7)/MasR Axes in Ang II-Infused Hypertensive Mice. [Abstract]2024 Dec;38(12):5918-5929. PMID: 39410864 -
Int Immunopharmacol
METTL14 downregulates GLUT9 through m6A methylation and attenuates hyperuricemia-induced fibrosis in mouse renal tubular epithelial cells. [Abstract]2024 Oct 10;143(Pt 1):113308. PMID: 39393275 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Solvent & Solubility
DMSO : ≥ 100 mg/mL (235.80 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (4.90 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 2.5 mg/mL (5.90 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (288 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Huang Z, et al. The protective effects of benzbromarone against propofol-induced inflammation and injury in human brain microvascular endothelial cells (HBMVECs) [J]. Neurotoxicity Research, 2021, 39(5): 1449-1458. [Content Brief]
[2]. Roos N J, et al. The uricosuric benzbromarone disturbs the mitochondrial redox homeostasis and activates the NRF2 signaling pathway in HepG2 cells [J]. Free Radical Biology and Medicine, 2020, 152: 216-226. [Content Brief]
[3]. Park J G, et al. Benzbromarone Induces Targeted Degradation of HSP47 Protein and Improves Hypertrophic Scar Formation [J]. Journal of Investigative Dermatology, 2023. [Content Brief]
[4]. Sun P, et al. Benzbromarone aggravates hepatic steatosis in obese individuals [J]. Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 2018, 1864(6): 2067-2077. [Content Brief]
[5]. Abdel-Razek E A N, et al. Benzbromarone mitigates cisplatin nephrotoxicity involving enhanced peroxisome proliferator-activated receptor-alpha (PPAR-α) expression [J]. Life sciences, 2020, 243: 117272. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3580 mL | 11.7902 mL | 23.5805 mL | 58.9511 mL |
| 5 mM | 0.4716 mL | 2.3580 mL | 4.7161 mL | 11.7902 mL | |
| 10 mM | 0.2358 mL | 1.1790 mL | 2.3580 mL | 5.8951 mL | |
| 15 mM | 0.1572 mL | 0.7860 mL | 1.5720 mL | 3.9301 mL | |
| 20 mM | 0.1179 mL | 0.5895 mL | 1.1790 mL | 2.9476 mL | |
| 25 mM | 0.0943 mL | 0.4716 mL | 0.9432 mL | 2.3580 mL | |
| 30 mM | 0.0786 mL | 0.3930 mL | 0.7860 mL | 1.9650 mL | |
| 40 mM | 0.0590 mL | 0.2948 mL | 0.5895 mL | 1.4738 mL | |
| 50 mM | 0.0472 mL | 0.2358 mL | 0.4716 mL | 1.1790 mL | |
| 60 mM | 0.0393 mL | 0.1965 mL | 0.3930 mL | 0.9825 mL | |
| 80 mM | 0.0295 mL | 0.1474 mL | 0.2948 mL | 0.7369 mL | |
| 100 mM | 0.0236 mL | 0.1179 mL | 0.2358 mL | 0.5895 mL |